Where Does Co-Diagnostics’ TB Test Fit in India’s NTEP?

Co-Diagnostics’ new Co-Dx PCR Pro tuberculosis test cannot replace Truenat or GeneXpert as a standalone frontline diagnostic in India’s National Tuberculosis Elimination Programme, even with regulatory approval. Because the test detects only tuberculosis bacteria without checking for Rifampicin drug resistance, every positive public-sector patient must still undergo a second molecular test.

Why Can’t the Co-Dx PCR Pro Tuberculosis Test Meet India’s Frontline NTEP Rules?

The Co-Dx PCR Pro tuberculosis test cannot serve as a standalone frontline diagnostic in India’s public health system because its cartridge detects only the presence of Mycobacterium tuberculosis bacteria without screening for Rifampicin drug resistance. Under India’s National Tuberculosis Elimination Programme (NTEP), the federal public health program that diagnoses and treats more than 2.5 million tuberculosis patients annually, every confirmed patient must receive a drug-resistance test before starting standard medication.

When Utah-based Co-Diagnostics, Inc. (Nasdaq: CODX) and its Indian joint venture, CoSara Diagnostics Pvt. Ltd., announced on October 27, 2026 that they had submitted their clinical trial dossier to the Central Drugs Standard Control Organization (CDSCO), India’s national medical device and pharmaceutical regulator, industry coverage treated regulatory clearance as the final step to competing across India’s public testing network. That framing omits the technical mismatch between what the cartridge measures and what Indian clinical regulations mandate.

According to Co-Diagnostics’ published technical specification sheet for the Co-Dx PCR Mycobacterium tuberculosis (MTB) Test Kit, the assay is designed solely “for detection of presence or absence of Mycobacteria tuberculosis” in tongue swabs and swabbed sputum samples. The instrument uses polymerase chain reaction (PCR), a laboratory method that copies small segments of bacterial DNA until they can be read by an optical sensor, to deliver a yes-or-no readout on a paired smartphone in under 40 minutes.

What the test cup does not measure is mutation in the rpoB gene, the genetic marker that identifies whether a patient’s tuberculosis strain is resistant to Rifampicin, the primary antibiotic used to cure standard tuberculosis. Nor does the test screen for resistance to Isoniazid, the second core first-line tuberculosis drug.

Under the Programmatic Management of Drug-Resistant Tuberculosis (PMDT) guidelines and the Universal Drug Susceptibility Testing (UDST) operational mandate enforced by the Central TB Division of India’s Ministry of Health and Family Welfare, every patient with bacteriologically confirmed tuberculosis must undergo Rifampicin resistance testing under NTEP protocols at the time of diagnosis. Universal Drug Susceptibility Testing is a federal clinical rule designed to stop clinics from placing a Rifampicin-resistant patient on standard first-line pills for six months, which fails to clear the infection and spreads drug-resistant strains.

India’s National Essential Diagnostics List (NEDL, 2nd Edition), published by the Indian Council of Medical Research (ICMR), the apex biomedical research body that validates diagnostics for Indian public health programs, reinforces this requirement. The ICMR diagnostic cascade routes presumptive tuberculosis samples from primary health centers directly to nucleic acid amplification test (NAAT) hubs, molecular diagnostic systems that amplify and detect bacterial genetic material rather than relying on microscope inspection, equipped to guide drug-resistance treatment. Without a Rifampicin readout, an Indian public clinic cannot use a positive Co-Dx PCR Pro result on its own to start a verified treatment regimen.

How Does the Co-Dx PCR Pro Workflow Compare With Truenat vs. GeneXpert in India?

While Molbio Diagnostics’ Truenat and Cepheid’s GeneXpert complete both tuberculosis detection and Rifampicin resistance testing from a single patient sample collection, a positive result on the Co-Dx PCR Pro requires collecting and referring a second specimen to another laboratory. That extra referral step occurs because the Co-Dx PCR Pro uses a sealed, single-use sample cup with no leftover purified DNA and no follow-up drug-resistance cartridge.

CoSara Diagnostics received its CDSCO Form MD-5 manufacturing license in February 2026 to build the portable Co-Dx PCR Pro analyzer at its facility in Ranoli, Gujarat. According to Co-Diagnostics’ October 27, 2026 press release, the joint venture evaluated 676 patient specimens in India, 233 of which (34.5%) were paired against Mycobacteria Growth Indicator Tube (MGIT) liquid culture, the multi-week laboratory reference test used as the gold standard to confirm live tuberculosis bacteria. Across three reagent batches, Co-Diagnostics reported 97.3% average sensitivity and 96.0% average specificity, with CDSCO marketing clearance anticipated by the company before the end of 2026.

In daily clinic operations, comparing the Co-Dx PCR Pro against Truenat vs. GeneXpert in India comes down to how many steps a technician needs to deliver both a tuberculosis diagnosis and a Rifampicin resistance answer:

• Cepheid GeneXpert (Xpert MTB/RIF Ultra): The cartridge processes sputum (phlegm coughed up from the deep lungs) in a single sealed chamber, reporting both M. tuberculosis detection and Rifampicin resistance simultaneously in under 80 minutes. One sample, one test run.
• Molbio Diagnostics Pvt. Ltd. Truenat (Truenat MTB Plus and MTB-RIF Dx): According to the Stop TB Partnership and Global Laboratory Initiative’s Practical Guide to Implementation of Truenat Tests, a technician first extracts DNA eluate, purified liquid DNA isolated from a sputum sample, in 20 minutes using a Trueprep extraction device. If the initial Truenat chip detects tuberculosis, the technician uses a micropipette to transfer 6 microliters of that leftover DNA eluate onto a follow-up Truenat MTB-RIF Dx chip on the same machine, delivering a Rifampicin resistance result within one hour without calling the patient back.
• Co-Diagnostics Co-Dx PCR Pro: According to Co-Diagnostics’ Co-Dx PCR MTB Test Kit component specifications, each 10-test box contains 10 single-use MTB test cups, 10 tongue swabs, 10 single-sample elution buffer ampules, and 10 sample lysis tubes with filtered lids, while the PCR Pro instrument and external sample lysis heater, a heating unit that breaks open bacterial cell walls to release DNA, are sold separately. Because the lysed sample goes directly into a closed, single-use MTB test cup and the CDSCO filing includes no Rifampicin reflex cup, a positive patient cannot complete NTEP’s mandatory drug-resistance check on the Co-Dx analyzer.

This hardware limitation hits clinics hardest when testing tongue swabs. Because tongue swabs capture far fewer bacterial cells than deep-lung sputum, a patient who tests positive via tongue swab on the Co-Dx PCR Pro must still produce a fresh sputum specimen for transport to a district hub running a Truenat or GeneXpert system.

What Do the March 2026 WHO NPOC-NAAT Tongue Swab Guidelines Say About Replacing Existing Tests?

The World Health Organization’s March 2026 guidelines on near-point-of-care nucleic acid amplification tests (NPOC-NAATs) explicitly instruct national health programs not to replace existing automated molecular systems like Truenat or GeneXpert with swab-based tests that lack drug-resistance detection. Instead, the World Health Organization classifies these devices as complementary screening tools that require referring every positive patient for secondary drug susceptibility testing.

In both its March 2026 trial shipment announcement and its October 27 regulatory update, Co-Diagnostics pointed to World Health Organization (WHO) tuberculosis updates to explain the demand for decentralized, swab-compatible PCR testing. What the company’s releases omitted is the operational restriction built into those WHO NPOC-NAAT tongue swab guidelines.

In March 2026, the WHO established the formal diagnostic class called near-point-of-care nucleic acid amplification tests (NPOC-NAATs), defined as battery-capable, swab-compatible molecular tests that operate without specialized laboratory infrastructure and return results in under an hour, but do not include drug susceptibility testing (DST).

In its official technical Frequently Asked Questions (FAQ) on NPOC-NAATs and tongue swabs, the WHO answered whether national TB programs should use these new point-of-care tests to replace established rapid molecular systems like Truenat (classified as low-complexity automated NAATs, or LC-aNAATs) or GeneXpert (moderate-complexity automated NAATs, or MC-aNAATs):

“No. WHO does not recommend replacing existing molecular WHO-recommended rapid diagnostic tests (WRDs), such as LC-aNAATs or MC-aNAATs, with NPOC-NAATs. NPOC-NAATs are intended to complement existing diagnostic networks, particularly in decentralized or hard-to-reach settings and in settings currently relying on smear microscopy.” World Health Organization, Frequently Asked Questions: Near point-of-care nucleic acid amplification tests (NPOC-NAATs), March 2026

In that same March 2026 WHO FAQ document, the agency warned national procurement officers about the exact cost and referral penalty triggered in countries with Rifampicin-resistant tuberculosis:

“NPOC-NAATs do not yet include drug susceptibility testing (DST). In settings with a high prevalence of rifampicin (RIF)-resistant TB, it may be more efficient to place or link facilities to existing LC-aNAAT/MC-aNAAT sites to ensure timely drug resistance results are available for care and avoid having to refer and retest all TB-positive samples at additional cost.” World Health Organization, Frequently Asked Questions: Near point-of-care nucleic acid amplification tests (NPOC-NAATs), March 2026

An independent February 2026 technical report and accompanying nPOC-NAAT operational factsheet published by the international medical humanitarian organization Médecins Sans Frontières (MSF) reinforced that boundary. According to MSF’s technical evaluation, first-generation nPOC-NAAT tools are less sensitive than automated systems like Truenat on low-bacterial-load samples and require health ministries to fund a parallel sample-transport network to retest every positive patient for drug resistance.

Where Does Co-Diagnostics’ India TB Test Fit After CDSCO Approval for CoSara Diagnostics?

Rather than replacing public clinic analyzers, Co-Diagnostics’ India TB test fits best in mobile community triage vans, village screening camps, and private clinics evaluating patients who cannot cough up sputum. Even after CDSCO approval for CoSara Diagnostics, the joint venture must still pass an independent Indian Council of Medical Research (ICMR) multi-site evaluation before India’s public health program can purchase a single test cup.

The strongest clinical use case for a presence-only, swab-compatible PCR test is active case finding (ACF), proactive community outreach that screens people in mobile vans and rural camps before they visit a hospital. According to the WHO Global Tuberculosis Report fact sheet, India accounts for roughly one-quarter of the world’s tuberculosis burden (about 2.5 million cases a year), and roughly 90% of newly diagnosed patients (about 2.25 million people annually in India) carry drug-sensitive strains rather than drug-resistant ones. Millions of presumptive patients evaluated in rural health sub-centers, especially children and people living with HIV, cannot expectorate the 2 milliliters of deep-lung sputum required by sputum-only cartridges.

In those outreach settings, screening 100 presumptive patients via tongue swab in 35-minute runs and referring only the 10 to 15 patients who test positive to a block-level Truenat hub for sputum-based Rifampicin testing can bring unreached patients into care. While Co-Diagnostics’ patented Co-Primers chemistry supports multiplexing (detecting multiple DNA targets in one reaction), the company’s published Co-Dx PCR platform pipeline currently lists only three follow-on tests in development: Human Papillomavirus (HPV), a Flu A/B–COVID-19–RSV upper respiratory panel, and a standalone COVID-19 assay, with no Rifampicin or Isoniazid resistance cartridge listed.

Being restricted to initial triage rather than frontline replacement changes the budget math for Indian procurement officers. Whenever a public health program uses a non-Rifampicin molecular test for primary screening, it pays twice for every positive patient: once for the initial Co-Dx screening cup, and a second time for the confirmatory Truenat or GeneXpert cartridge, plus the cost of transporting the patient or a fresh sputum sample between clinics.

Public procurement pricing leaves little room for duplicate testing. According to the Stop TB Partnership’s Global Drug Facility (GDF) Diagnostics Catalog, Molbio’s Truenat MTB and MTB Plus tests are supplied at $9.00 (roughly ₹750) per test with free replacement Rifampicin reflex chips included for positive cases, while the WHO notes in its March 2026 NPOC-NAAT FAQ that first-generation swab tests need to be priced lower than automated molecular tests to offset two-step referral costs. Co-Diagnostics and CoSara Diagnostics have not yet disclosed commercial prices for the Co-Dx PCR Pro analyzer, its separately sold lysis heater, or its single-use MTB test cups.

Even if the CDSCO grants CoSara Diagnostics marketing clearance before the end of 2026, a CDSCO license only authorizes sales to private laboratories and hospital chains. Before a single Co-Dx PCR Pro test cup can enter India’s public NTEP clinics, CoSara must submit the device for independent validation under the ICMR-CDSCO Standard Performance Evaluation Protocols and prove how a test that cannot detect drug resistance fits inside a national program legally bound to test every confirmed patient for it.

Frequently Asked Questions

Does the Co-Dx PCR Pro tuberculosis test detect Rifampicin drug resistance?

No. According to Co-Diagnostics’ technical specification sheet for the Co-Dx PCR Mycobacterium tuberculosis (MTB) Test Kit, the single-use test cup only detects the presence or absence of tuberculosis bacteria in tongue swabs or swabbed sputum. It does not screen for mutations in the rpoB gene that cause Rifampicin resistance, and Co-Diagnostics’ published PCR pipeline does not list a Rifampicin or Isoniazid resistance cartridge in development.

Why does India’s National Tuberculosis Elimination Programme require Rifampicin testing?

Under Universal Drug Susceptibility Testing (UDST) guidelines enforced by the Central TB Division of India’s Ministry of Health and Family Welfare, every bacteriologically confirmed tuberculosis patient must be tested for Rifampicin resistance at diagnosis. Giving standard six-month first-line antibiotics to a patient with Rifampicin-resistant tuberculosis fails to cure the infection and spreads drug-resistant strains.

How does Molbio’s Truenat handle Rifampicin resistance differently from the Co-Dx PCR Pro?

When a patient tests positive for tuberculosis on Molbio Diagnostics’ Truenat analyzer, a technician pipettes 6 microliters of leftover purified DNA eluate from the initial sputum extraction onto a follow-up Truenat MTB-RIF Dx chip on the same machine to determine Rifampicin resistance within one hour. Because the Co-Dx PCR Pro places the sample into a closed, single-use cup with no leftover purified eluate or follow-up resistance chip, a positive patient must provide a second specimen for referral to a Truenat or GeneXpert facility.

Does CDSCO approval allow CoSara Diagnostics to sell the Co-Dx PCR Pro to India’s public TB program?

No. Marketing approval from India’s Central Drugs Standard Control Organization (CDSCO) only authorizes commercial sales to private laboratories and private hospitals. To qualify for public procurement tenders under the National Tuberculosis Elimination Programme (NTEP), CoSara Diagnostics must pass a separate multi-site clinical evaluation conducted by the Indian Council of Medical Research (ICMR).